

Daily evidence digest

4 April 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Phase 3 trial of a DNA vaccine, risk of reinfection and hospitalisation with natural and hybrid immunity, human challenge trial, influenza under COVID

Peer reviewed journals featured:

- A systematic review on pulse oximetry in remote patient monitoring of COVID-19 patients [here](#)
- A phase 3 trial of a DNA COVID-19 vaccine, ZyCoV-D [here](#) and associated commentary [here](#)
- Observational studies on:
 - Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity [here](#) and associated commentary [here](#)
 - SARS-CoV-2 human challenge in young adults [here](#) and associated commentary [here](#)
 - Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination [here](#)
 - Defining the risk of SARS-CoV-2 variants on immune protection [here](#)
 - Effectiveness of CoronaVac, Vaxzevria, Comirnaty, and Janssen in people with previous SARS-CoV-2 infection in Brazil [here](#) and associated commentary [here](#)
 - Association between primary care practice telehealth use and acute care visits for ambulatory care-sensitive conditions during COVID-19 in Michigan [here](#)
 - Biocidal efficacy of commercial disinfectants used in public, private and workplaces during COVID-19 [here](#)
 - UK rates and disparities in childhood vaccination and vaccine-preventable disease [here](#)
 - Short-term exposure to ambient air pollution and individual emergency department visits for COVID-19 in Canada [here](#)
- A modelling study analysing the characteristics associated with COVID-19 mortality [here](#)
- An editorial on a roadmap of recovery for the COVID-19 generation [here](#)
- Commentary on:
 - Strategies to improve global COVID-19 vaccine equity and pandemic preparedness [here](#)
 - Reducing “COVID-19 misinformation” while preserving free speech in the US [here](#)
 - How Japan survived COVID-19 [here](#)
 - Should COVID-19 vaccines and drugs be “not for profit”? [here](#)
 - Mixed response to COVID-19 intellectual property waiver [here](#)

Letters and correspondence discussed:

- A published article on cellular responses to COVID-19 vaccination after B-cell depletion [here](#)

Pre-peer review articles featured:

- Rapid increase in SARS-CoV-2 seroprevalence during the emergence of Omicron in Finland [here](#)
- Estimating the value of more clinical trials on emerging therapies for COVID-19 [here](#)
- The unmitigated downside risks of widespread SARS-CoV-2 transmission [here](#)
- The effect of prior vaccination on immune response to Omicron infection [here](#)
- Outcomes in unvaccinated COVID-19 cases among people <18 years old in Norway [here](#)

Guidance and reports

- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)
- The Australian Technical Advisory Group Immunisation (ATAGI) recommended a winter COVID-19 booster to specified population groups [here](#)
- The Australian Health Protection Principal Committee (AHPPC) released a statement on winter season preparedness [here](#)

News and blogs

- Hong Kong's fifth COVID-19 wave [here](#)
- Diabetes risk rises after COVID-19 [here](#)
- Disincentives for vaccine refusal [here](#)
- Lockdowns spread in China as Omicron tests “zero covid” strategy [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).